RECRUITING

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Conditions

Postural Tachycardia Syndrome Postural tachycardia syndrome (POTS)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Official Title

Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome

Quick Facts

Study Start:2006-10

Study Completion:2025-02

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT00409435

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 55 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt. * Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.	* Pregnant or lactating women * Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study * Hypothyroidism or hyperthyroidism * Clinically significant coronary artery disease * Medications that could interfere with autonomic testing * Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month

Inclusion Criteria

Exclusion Criteria

* Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
* Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.

* Pregnant or lactating women
* Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
* Hypothyroidism or hyperthyroidism
* Clinically significant coronary artery disease
* Medications that could interfere with autonomic testing
* Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month

Contacts and Locations

Principal Investigator

Phillip A. Low, M.D.

PRINCIPAL_INVESTIGATOR

Mayo Clinic

Study Locations (Sites)

Mayo Clinic

Rochester, Minnesota, 55905

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Phillip A. Low, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2006-10

Study Completion Date2025-02

Study Record Updates

Study Start Date2006-10

Study Completion Date2025-02

Terms related to this study

Keywords Provided by Researchers

Postural tachycardia syndrome (POTS)

Additional Relevant MeSH Terms

Postural Tachycardia Syndrome